TIDMAMS
RNS Number : 5116V
Advanced Medical Solutions Grp PLC
14 April 2021
14 April 2021
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the surgical and advanced wound care specialist company , announces
the following PDMR share transactions.
As part of the Company's Deferred Share Bonus Plan (DSB),
Executive Directors and employees can sacrifice part of their
annual bonus to be invested in the DSB, which for every share
purchased on behalf of the employee they receive matching shares
which are deferred for a minimum of three years. As a result of
there being no Executive bonuses being awarded for the financial
year ended 31 December 2020 due to the financial impact of
COVID-19, Chris Meredith (CEO) and Eddie Johnson (CFO) have elected
to sell certain existing shares to use the proceeds to re-invest in
the DSB. The decision to participate in the DSB was taken on 7
April 2021.
The Company was notified on 9 April 2021 that following his
decision to participate on 7 April, Chris Meredith, who is a
Director and PDMR, executed the exercise of 23,369 options from the
existing Deferred Annual Bonus Plan (DAB) . Chris Meredith elected
to receive an additional 272 dividend shares which were earned
during the holding period under the terms of the DAB. Chris
Meredith has also executed the exercise of 3,010 Ordinary Shares of
5p from the existing DSB and subsequently sold 28,156 Ordinary
Shares of 5p each on 9 April 2021 at a share price of 241p per
Ordinary Share. The proceeds from the sale of the shares will be
used to purchase shares in the DSB which administratively occurs in
May 2021, and will increase Chris Meredith's beneficial interest in
the Company from the level prior to these transactions.
As a result of these transactions Chris Meredith's beneficial
interest in the Company is as follows, prior to the purchase of
shares in May 2021:
Deferred Share Bonus Plan (DSB)
PDMR No. of DSBs DSBs exercised Ordinary Ordinary DSBs after
prior to exercise Shares sold Shares retained exercise
Chris Meredith 60,300 3,010 3,010 Nil 57,290
------------------- --------------- ------------- ----------------- -----------
Deferred Annual Bonus Plan (DAB)
PDMR DABs prior DABs exercised Dividend Ordinary Ordinary DABs after
to exercise Shares received Shares Shares retained exercise
sold
Chris Meredith 57,977 23,369 272 23,641 Nil 34,608
------------- --------------- ----------------- --------- ----------------- -----------
Overall Holding
PDMR Holding Number Dividend Number Sale price Resultant % of issued
prior of shares Shares of shares (p) holding share capital
to exercise exercised received sold
Chris Meredith 1,511,550 26,379 272 28,156 241p 1,510,045 0.7%
------------- ----------- ---------- ----------- ----------- ---------- ---------------
The Company was notified on 9 April 2021 that following his
decision to participate on 7 April, Eddie Johnson , who is a
Director and PDMR, executed the exercise of 17,254 Ordinary Shares
of 5p from the existing DSB and subsequently sold 19,193 Ordinary
Shares of 5p each on 9 April 2021 at a share price of 241p per
Ordinary Share. The proceeds from the sale of the shares will be
entirely used to purchase shares in the DSB which administratively
occurs in May 2021, and will increase Eddie Johnson's beneficial
interest in the Company from the level prior to these
transactions.
As a result of these transactions Eddie Johnson's beneficial
interest in the Company is as follows, prior to the purchase of
shares in May 2021:
Deferred Share Bonus Plan (DSB)
PDMR No. of DSBs DSBs exercised Ordinary Ordinary DSBs after
prior to exercise Shares sold Shares retained exercise
Eddie Johnson 91,618 17,254 17,254 Nil 74,364
------------------- --------------- ------------- ----------------- -----------
Overall Holding
PDMR Holding Number Dividend Number Sale price Resultant % of issued
prior of shares Shares of shares (p) holding share capital
to exercise exercised received sold
Eddie Johnson 67,967 17,254 0 19,193 241p 66,028 0.03%
------------- ----------- ---------- ----------- ----------- ---------- ---------------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Chris Meredith
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Director/PDMR
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc
---------------------------------------------------------------------
b) LEI: 213800HJP6OWOSZI1L74
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of instrument:
Ordinary Shares of 5p
Identification code: GB0004536594
---------------------------------------------------------------------
b) Nature of the transactions:
* Exercise of 23,369 shares from the Deferred Annual
Bonus Plan
* Award of 272 Dividend Shares from the Deferred Annual
Bonus Plan
* Exercise of 3,010 shares from the Deferred Share
Bonus Plan
* Sale of 28,156 Ordinary Shares of 5p
---------------------------------------------------------------------
c) Price(s) and volume(s):
Sale of shares: Price(s) Volume(s)
GBP2.41 28,156
----------
---------------------------------------------------------------------
d) Aggregated information: (Relates to those shares sold
only)
Aggregated volume: 28,156
Aggregated price: GBP2.41
---------------------------------------------------------------------
e) Date of the transaction: 09/04/2021
---------------------------------------------------------------------
f) Place of the transaction: London Stock Exchange, AIM
Market (XLON)
---------------------------------------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Eddie Johnson
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Director/PDMR
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc
---------------------------------------------------------------------
b) LEI: 213800HJP6OWOSZI1L74
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of instrument:
Ordinary Shares of 5p
Identification code: GB0004536594
---------------------------------------------------------------------
b) Nature of the transaction:
* Exercise of 17,254 shares from the Deferred Share
Bonus Plan
* Sale of 19,193 Ordinary Shares of 5p
---------------------------------------------------------------------
c) Price(s) and volume(s):
Sale of shares: Price(s) Volume(s)
GBP2.41 19,193
----------
---------------------------------------------------------------------
d) Aggregated information: (Relates to those shares sold
only)
Aggregated volume: 19,193
Aggregated price: GBP2.41
---------------------------------------------------------------------
e) Date of the transaction: 09/04/2021
---------------------------------------------------------------------
f) Place of the transaction: London Stock Exchange, AIM
Market (XLON)
---------------------------------------------------------------------
-End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Olivia AMS@consilium-comms.com
Manser
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence / Patrick
Robb
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, and
internal fixation devices, which it markets under its brands
LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also
supplies wound care dressings such as silver alginates, alginates
and foams through its ActivHeal(R) brand as well as under white
label. In 2019, the Group made two acquisitions: Sealantis, an
Israeli medical device company with a patent-protected sealant
technology platform; and Biomatlante, an established developer and
manufacturer of innovative surgical biomaterial technologies based
in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a
leading coater and converter of materials predominately for
woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, and the Czech Republic, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has approximately 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBRGDSIGBDGBS
(END) Dow Jones Newswires
April 14, 2021 13:13 ET (17:13 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From May 2023 to May 2024